Core Viewpoint - Conavi Medical Corp. has filed a preliminary short form prospectus for an offering of common shares and/or pre-funded common share purchase warrants to support the launch of its Novasight Hybrid system and for general corporate purposes [2][4]. Offering Details - The offering will be conducted on a commercially reasonable efforts agency basis through Bloom Burton Securities Inc. [3] - The final terms, including the number of securities and pricing, will be determined through negotiations between the company and the agent [3]. - The expected closing date for the offering is around December 12, 2025, subject to customary closing conditions and regulatory approvals [5]. Use of Proceeds - The net proceeds from the offering will be utilized to obtain US FDA 510(k) clearance for the Novasight Hybrid system, complete a limited market release, and initiate a broader commercial launch in the United States [4]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [9]. - The Novasight Hybrid™ System combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, allowing simultaneous imaging of coronary arteries [9][10].

Core Insights - Conavi Medical has appointed Mark Quick as Chief Financial Officer to support its U.S. expansion and commercialization efforts for the Novasight Hybrid imaging system [1][3][5] - The company has submitted its next-generation Novasight Hybrid IVUS/OCT system to the FDA for 510(k) clearance, aiming for a successful launch in the U.S. market [2][5] - Stefano Picone transitions to a strategic role as Chief Strategy Officer, focusing on ensuring continuity during the company's growth phase [1][4][5] Leadership Changes - Mark Quick brings over 20 years of experience in medical technology and life sciences, having held senior financial roles in publicly traded companies [3][6] - Stefano Picone has played a crucial role in Conavi's previous growth phases and will now concentrate on strategic execution [4][5] Product Development - The Novasight Hybrid System is the first device to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT), allowing simultaneous imaging of coronary arteries [7] - The first-generation Novasight Hybrid System has already received regulatory clearance in multiple countries, including the U.S., Canada, China, and Japan [7] Market Strategy - The company is actively building the necessary infrastructure to support its U.S. launch, which is critical as the U.S. is the largest market for intravascular imaging [2][5] - Leadership changes are aligned with the company's strategy to enhance its presence in the capital markets and ensure successful commercialization [1][5]

Core Insights - Conavi Medical Corp. has entered into an agreement with the Province of Ontario under the Life Sciences Scale-Up Fund (LSSUF) to support the commercial launch of its next-generation Novasight Hybrid™ system [1][2][3] Group 1: Financial Support and Project Details - The LSSUF will provide Conavi with up to $2.5 million CAD, covering up to one-third of eligible project costs related to the Novasight Hybrid™ system [2] - The funding is contingent upon meeting certain requirements as part of the project [2] Group 2: Product and Technology - The Novasight Hybrid™ system integrates intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, offering comprehensive imaging of coronary arteries [3][4] - This dual-modality approach aims to enhance the precision of diagnosis and treatment for cardiovascular diseases [3] Group 3: Industry Context and Impact - Heart disease is a leading cause of death in Canada and globally, highlighting the importance of advancements in intravascular imaging technologies [3] - The partnership with the Province of Ontario is expected to reinforce the region's position as a leader in life sciences innovation [3]

Core Points - Conavi Medical Corp. is a commercial-stage medical device company focused on imaging technologies for minimally invasive cardiovascular procedures [1][3] - The company will present at the Planet MicroCap Showcase: TORONTO 2025 on October 22, 2025, at 9:30 AM EST [1][2] - Tom Looby, the CEO of Conavi Medical, will host the presentation and answer questions afterward [1] Company Overview - Conavi Medical specializes in designing, manufacturing, and marketing imaging technologies, particularly the Novasight Hybrid™ System [3] - The Novasight Hybrid™ System is the first device to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries [3] - The first-generation Novasight Hybrid™ System has received regulatory clearance in the U.S., Canada, China, and Japan [3] Event Details - The Planet MicroCap Showcase: TORONTO 2025 is organized in partnership with MicroCapClub [4] - Live presentations will be accessible via a webcast link provided for attendees [2][3] - Attendees can schedule 1x1 investor meetings with Conavi Medical during the conference [2]

Core Insights - Conavi Medical Corp. reported its financial results for the fiscal quarter ended June 30, 2025, highlighting significant developments in its product pipeline and financial position [1][11]. Business Highlights - The company completed successful validation testing of its next-generation Novasight™ system with leading interventional cardiologists, confirming its competitiveness with existing IVUS and OCT solutions [2][3]. - A $20 million financing round completed in April 2025 strengthens the company's balance sheet, providing resources for regulatory submission and production transition [6][8]. Regulatory and Production Milestones - Conavi is on track to submit its 510(k) application to the U.S. FDA in Q3 2025, which is crucial for its planned U.S. launch in the first half of 2026 [4][10]. - The transition of the Novasight system from development to manufacturing is underway, expected to align with the U.S. launch timeline [4]. Financial Performance - For Q3 FY 2025, the company recorded revenue of CAD 63,000, a decrease from CAD 401,000 in the same period the previous year [11]. - Operating expenses were CAD 4.7 million, down from CAD 8.8 million year-over-year, leading to a reduced operating loss of CAD 4.6 million compared to CAD 8.9 million in Q3 FY 2024 [12]. - The net loss for Q3 FY 2025 was CAD 3.6 million, or CAD 0.05 per share, significantly improved from a net loss of CAD 13.0 million, or CAD 2.12 per share, in the prior year [13]. Market Context - A publication in the Journal of the American College of Cardiology emphasizes the growing importance of intravascular imaging in treating complex coronary artery disease, indicating a favorable market environment for Conavi's hybrid imaging technology [2][5].

Core Insights - Conavi Medical Corp. is hosting a live webinar to discuss its innovative imaging technology for minimally invasive cardiovascular procedures [1][2] - The CEO, Tom Looby, will present the company's market-leading Novasight Hybrid™ System, which combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [1][3] - The Novasight Hybrid System has received regulatory approvals from the U.S. FDA, Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare [3] Event Details - The webinar is scheduled for June 24th at 4 PM ET / 1 PM PT, and will include a Q&A session for attendees [2] - A recording of the event will be available for those unable to attend live [2] - Radius Research, part of Market Radius Capital, Inc., will host the event, providing individual investors with access to in-depth discussions [2] Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies specifically for cardiovascular procedures [3] - The Novasight Hybrid™ System is the first of its kind to enable simultaneous imaging of coronary arteries using both IVUS and OCT [3]

Core Points - Conavi Medical Corp. has approved the grant of 5,849,098 stock options to its directors, officers, employees, and consultants under its Omnibus Equity Incentive Plan [1] - The stock options are exercisable at a price of $0.39 CAD per share for a period of 10 years from the grant date [1] - The allocation of stock options includes 1,930,172 options to independent directors and 3,581,216 options to officers, with the remainder going to other employees and consultants [2][3] Allocation Details - Independent directors received the following stock options: Anthony Giovinazzo (341,624), Cathy Steiner (341,624), Robert Mitchell (330,807), Susan Allen (358,242), and Aaron Davidson (557,875) [2] - Officers received the following stock options: Travis More (298,413), Amandeep Thind (266,863), Sumeet Dham (393,924), Stefano Picone (425,000), and Thomas Looby (2,197,646) [3] Audit Committee Changes - Minor changes were made to the composition of the Audit Committee, with Aaron Davidson stepping down and Susan Allen, Cathy Steiner, and Robert Mitchell continuing to serve [4] Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [5] - The Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries [5] - The system has received regulatory approvals from the U.S. FDA, Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare [5]

Core Insights - Conavi Medical Corp. announced financial results for Q1 2025, reporting a revenue of approximately CAD 58,000, a significant decrease from CAD 589,000 in the same period last year [8][9] - The company raised CAD 20 million in financing to support the development and commercial launch of the next-generation Novasight Hybrid system, with U.S. institutional investors participating [2][5] - New U.S. intracoronary imaging guidelines validate the clinical utility of the Novasight system, which combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [5][6] Financial Performance - For Q2 2025, operating expenses were approximately CAD 5.6 million, down from CAD 6.0 million in Q2 2024, primarily due to reduced research and development costs [9] - The net loss for Q2 2025 was approximately CAD 3.1 million, or CAD 0.07 per share, compared to a net loss of CAD 7.1 million, or CAD 1.15 per share, in Q2 2024 [10] - As of March 31, 2025, cash and cash equivalents were approximately CAD 1.0 million, an increase from CAD 0.4 million as of September 30, 2024 [11] Product Development and Regulatory Milestones - The company is on track for a U.S. FDA 510(k) submission for the next-generation Novasight system in Q3 2025 [3][5] - Expected completion of usability and system validation with key opinion leaders is set for Q4 2025 [4] - The planned commercial launch of the Novasight Hybrid system is anticipated in H1 2026 [5][6] Market Position and Strategy - The recent financing and new medical guidelines position Conavi Medical to unlock substantial shareholder value [2][5] - The company aims to improve investor transparency and visibility through uplisting to the OTCQB [6] - Upcoming publications in academic journals are expected to drive awareness of the Novasight system [7]

Core Insights - Conavi Medical's Novasight Hybrid™ System has been awarded "Product Innovation of the Year" at the 2025 Minnesota Manufacturing Awards, highlighting its significant advancement in intracoronary imaging technology [1][2][3] Company Overview - Conavi Medical is a medical device company focused on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [4] - The Novasight Hybrid™ System is the first device to integrate intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries, providing comprehensive insights for interventional cardiologists [2][4] Industry Recognition - The Minnesota Manufacturing Awards celebrate innovation, leadership, and growth within Minnesota's manufacturing sector, with Conavi Medical and Novasight being featured in a special publication by the Minneapolis/St. Paul Business Journal [3]